A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age.
about
Best practice in the prevention and management of paediatric respiratory syncytial virus infectionStable long-term cultures of self-renewing B cells and their applicationsSelf-assembling protein nanoparticles in the design of vaccinesSynthetic Biodegradable Microparticle and Nanoparticle Vaccines against the Respiratory Syncytial VirusWhat Are the Most Powerful Immunogen Design Vaccine Strategies?Respiratory Syncytial Virus: Infection, Detection, and New Options for Prevention and Treatment.RSV vaccine use--the missing data.Immunogenicity and safety of a respiratory syncytial virus fusion protein (RSV F) nanoparticle vaccine in older adults.Clinical Presentation and Birth Outcomes Associated with Respiratory Syncytial Virus Infection in Pregnancy.Absence of Association between Cord Specific Antibody Levels and Severe Respiratory Syncytial Virus (RSV) Disease in Early Infants: A Case Control Study from Coastal KenyaSendai virus as a backbone for vaccines against RSV and other human paramyxovirusesToward Developing a Preventive MERS-CoV Vaccine-Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14-15, 2015.Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV.Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein.A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant.Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine DesignStrategies to develop vaccines of pediatric interest.Development of an intradermal DNA vaccine delivery strategy to achieve single-dose immunity against respiratory syncytial virus.Ongoing developments in RSV prophylaxis: a clinician's analysis.Passive and active immunization against respiratory syncytial virus for the young and old.Determining the Seasonality of Respiratory Syncytial Virus in the United States: The Impact of Increased Molecular Testing.The role of nanotechnology in the treatment of viral infections.Dynamics of 8G12 competitive antibody in "prime-boost" vaccination of Hepatitis E vaccine.Immunization with Low Doses of Recombinant Postfusion or Prefusion Respiratory Syncytial Virus F Primes for Vaccine-Enhanced Disease in the Cotton Rat Model Independently of the Presence of a Th1-Biasing (GLA-SE) or Th2-Biasing (Alum) Adjuvant.Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.Influence of antigen conformation and mode of presentation on the antibody and protective responses against human respiratory syncytial virus: relevance for vaccine development.Protection of calves by a prefusion-stabilized bovine RSV F vaccine.Pre-fusion RSV F strongly boosts pre-fusion specific neutralizing responses in cattle pre-exposed to bovine RSV.The Outpatient Burden of Respiratory Syncytial Virus Infections in Older Children.Vaccines Against Respiratory Syncytial Virus: The Time Has Come.Do recombinant-engineered nanoparticle vaccines hold promise for the prevention of respiratory syncytial virus?ENHANCING THE THERMOSTABILITY AND IMMUNOGENICITY OF AN RSV LIVE-ATTENUATED VACCINE BY INCORPORATING UNIQUE RSV LINE19F PROTEIN RESIDUES.Burden of Respiratory Syncytial Virus Infection in South African Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Pregnant and Postpartum Women: A Longitudinal Cohort Study.Vaccines for the Paramyxoviruses and Pneumoviruses: Successes, Candidates, and Hurdles.Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children.Induction and Subversion of Human Protective Immunity: Contrasting Influenza and Respiratory Syncytial Virus.Efficacy of a respiratory syncytial virus vaccine candidate in a maternal immunization model.Respiratory Syncytial Virus Vaccine Approaches: a Current Overview.
P2860
Q26749036-8CC7D6E1-CD1F-44DD-B14F-E3AECF16962EQ26766723-ECA15CF9-72A0-4CFE-9B08-735C9EC670B0Q26767097-AFA90C9F-868B-45F4-B114-D7681D826E57Q28067143-4AAB87B7-01F0-4F1C-9182-8C04B5D75425Q28729792-845B00B5-5A2B-4E7D-811C-8150EE27533AQ30240274-2C8E9991-86B0-499F-A45A-25CE53D29A14Q31030277-AAFA0A2E-8C27-41C9-94E2-9DC541401AE4Q33555911-D576A787-BD9B-4DAF-970E-8681505475CBQ35975363-342302B2-A3E9-416A-AE56-CA7AF3B76A17Q36194104-747E8D7E-D026-45CB-A0B2-ABE4DB34A2B3Q37118707-455551C3-92C0-4612-842E-52CF8F65A456Q37169882-D31EC474-FFC1-4FF8-A24C-60FBDF2BE4F2Q37242530-84B5F911-734C-42E8-B8CD-2A128FBBA085Q37398188-445209DF-85CD-4996-996D-2E9526CD043FQ37578458-FE5A18F7-28A5-4051-B017-EA62B5783AA3Q37729137-32BEB746-5A23-47CE-8416-19CEDC837AC2Q38819027-8CB80564-DEF2-48B7-B5BF-07A71F4CE77EQ38835118-E0ABA2DD-1919-4037-B794-AD73768B3424Q39303791-2F922263-CC26-4A96-891B-E2A059B46A18Q39318498-1C86BF5E-D051-45C2-9838-4CD48ED2A2CAQ40062704-6DC84545-A2A1-4FD1-B180-1FA57C7D60B7Q40106774-3DB0CAC4-4835-4698-ABD7-B391DEF2C681Q40302625-2D38A5D5-698E-4F3B-BF40-CCEC3B79E764Q40349822-7F389E44-E393-473D-A610-1579A1B5A7AFQ40355982-B4C4101F-7F0B-4A59-84FA-8B9EAD64B304Q40812866-0444F932-2859-47F0-8944-25859BA424FEQ41918616-373AE056-0CBF-432C-BA25-AC4A46838AD1Q42652733-85C0F0C6-29DF-4F92-B096-CE3D5F97BF58Q45332698-B9B32448-8768-495C-A612-57929723748EQ45332913-16930662-0555-49F6-A1E4-C45954D51003Q45338183-D8AD7BB8-6BF8-4727-9D83-B458FD100746Q47269161-D87791E0-E2C4-45E3-8A1E-D859A1087217Q47290585-D1EF143D-E9B8-40D4-85B5-25633D058AABQ47555408-601CAA5A-95DA-40F4-A47F-69413912D80CQ50262223-5DAE8B69-7A16-4D8F-93F2-7F793B5ECF5CQ52649839-C7447316-DD2E-480E-879A-962281EE70A0Q55079643-A9192210-7B7F-46F9-9206-B90B664EE835Q55534670-BB2CEFEE-9295-43A7-BB2B-270EAD8E91B1
P2860
A Randomized, Blinded, Controlled, Dose-Ranging Study of a Respiratory Syncytial Virus Recombinant Fusion (F) Nanoparticle Vaccine in Healthy Women of Childbearing Age.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
A Randomized, Blinded, Control ...... thy Women of Childbearing Age.
@en
type
label
A Randomized, Blinded, Control ...... thy Women of Childbearing Age.
@en
prefLabel
A Randomized, Blinded, Control ...... thy Women of Childbearing Age.
@en
P2093
P2860
P921
P356
P1476
A Randomized, Blinded, Control ...... thy Women of Childbearing Age.
@en
P2093
D Nigel Thomas
David Flyer
Dewal Jani
Eloi Kpamegan
Gale Smith
Gregory M Glenn
Louis F Fries
Pedro A Piedra
Somia P Hickman
P2860
P304
P356
10.1093/INFDIS/JIV406
P407
P577
2015-08-10T00:00:00Z